Table 2.
Anti-spike antibody levels.
| Dialysis Patients Post Vaccination (n = 142) |
Dialysis Patients Post COVID-19 Infection (n = 33) |
Control Group (n = 104) |
p-Value | |
|---|---|---|---|---|
| One month Anti-spike antibody (AU/mL) median (25–75) |
118 (70.3–157.0) |
116 (62.3–193) |
186 (144.5–232) |
p1 = 1.00 p2,3 < 0.001 |
| 3-month anti-spike antibody (AU/mL) median (25–75) |
63 (24–100) (n = 41) |
203 (120–396) (n = 18) |
p1 < 0.001 | |
| 6-month anti-spike antibody (AU/mL), median (25–75) |
33 (14.6–70.2) |
273 (88–400) |
133 (93–196) | p1,2 < 0.001 |
| Negative anti-spike result (<15 AU/mL), no (%) |
38 (27) | 0 | 0 | p1,2 < 0.001 |
| Anti-spike level change (%) over 6 months | −66 ((−78)–(−48)) | +48 (0.4, 227) | −27.7 ((−38)–(−11)) |
p1,2 < 0.001 p3 = 0.017 |
| Anti-spike level change (%) 1–3 months |
–51 ((−66)–(−35)) |
+45 ((−3)–(203)) |
p < 0.001 |
p1 dialysis patients post vaccination vs. post infection dialysis patients (Group 1 vs. Group 2); p2 dialysis patients post vaccination vs. control group (Group 1 vs. Group 3); p3 post infection dialysis patients vs. control group (Group 2 vs. Group 3).